Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Creative Medical Technology Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SELECTS GREENSTONE BIOSCIENCES TO ACCELERATE AI-DRIVEN IPSC PRECISION MEDICINE PLATFORM SELECTS GREENSTONE BIOSCIENCES TO ACCELERATE AI-DRIVEN IPSC PRECISION MEDICINE PLATFORM

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. IGNITES NEXT-GEN REGENERATIVE BIODEFENSE INITIATIVE FOR U.S. VETERANS EXPOSED TO BURN PITS

PHOENIX, OCT. 29, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., (NASDAQ: CELZ) (THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING REGENERATIVE IMMUNOTHERAPY, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AGREEMENTS WITH CERTAIN HOLDERS OF ITS EXISTING WARRANTS FOR THE IMMEDIATE EXERCISE OF OUTSTANDING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 1,116,136 SHARES OF COMMON STOCK OF THE COMPANY ORIGINALLY ISSUED IN MARCH 2025, AT THEIR CURRENT EXERCISE PRICE OF $3.75 PER SHARE. THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE EXISTING WARRANTS ARE REGISTERED PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT ON FORM S-3 (FILE NO.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES AGREEMENTS FOR EXERCISE OF WARRANTS FOR $4.2 MILLION GROSS PROCEEDS

ONGOING PHASE II CLINICAL TRIALS, RECENTLY ISSUED PATENTS, AND AI INTEGRATION INITIATIVESSET THE STAGE FOR CONTINUING PROGRESS IN 2026 ONGOING PHASE II CLINICAL TRIALS, RECENTLY ISSUED PATENTS, AND AI INTEGRATION INITIATIVESSET THE STAGE FOR CONTINUING PROGRESS IN 2026

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ISSUES LETTER TO SHAREHOLDERS

RECENT ISSUANCE OF U.S. PATENTS COVERING IMMCELZ  SUPERCHARGED REGULATORY T CELL PROGRAMS IN HEART FAILURE AND TYPE 1 DIABETES REINFORCE CREATIVE MEDICAL'S SIMILAR RESEARCH FOCUS RECENT ISSUANCE OF U.S. PATENTS COVERING IMMCELZ  SUPERCHARGED REGULATORY T CELL PROGRAMS IN HEART FAILURE AND TYPE 1 DIABETES REINFORCE CREATIVE MEDICAL'S SIMILAR RESEARCH FOCUS

CREATIVE MEDICAL TECHNOLOGY HOLDINGS CONGRATULATES 2025 NOBEL LAUREATES FOR REGULATORY T CELL BREAKTHROUGHS

PHOENIX, JULY 17, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) (CREATIVE MEDICAL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY SPECIALIZING IN REGENERATIVE MEDICINE, TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTICE OF ALLOWANCE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR A U.S. PATENT APPLICATION TITLED, PREVENTION AND/OR TREATMENT OF TYPE 1 DIABETES BY AUGMENTATION OF MYELOID SUPPRESSOR CELL ACTIVITY.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS RECEIVES NOTICE OF ALLOWANCEFOR THE PREVENTION AND/OR TREATMENT OF TYPE 1 DIABETES USING MODULATED IMMUNE CELLS

PHOENIX, JULY 11, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) (CREATIVE MEDICAL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY SPECIALIZING IN REGENERATIVE MEDICINE, TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTICE OF ALLOWANCE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR A U.S. PATENT APPLICATION TITLED, TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLS.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS RECEIVES NOTICE OF ALLOWANCE FOR IMMCELZ FOR TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING

POSITIVE INTERIM BLINDED DATA SUPPORTS ADVANCEMENT TOWARDPOTENTIAL PIVOTAL PHASE 3 STUDY POSITIVE INTERIM BLINDED DATA SUPPORTS ADVANCEMENT TOWARDPOTENTIAL PIVOTAL PHASE 3 STUDY

CREATIVE MEDICAL TECHNOLOGY HOLDINGS SECURES FDA CLEARANCE FOR EXPANDED DOSE ESCALATION IN THE CLINICAL TRIAL OF CELZ-201-DDT FOR CHRONIC LOWER BACK PAIN

PHOENIX, MARCH 06, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., (NASDAQ: CELZ) (THE COMPANY), A LEADING BIOTECHNOLOGY INNOVATOR IN REGENERATIVE MEDICINE, TODAY ANNOUNCED IT HAS ENTERED INTO AGREEMENTS WITH CERTAIN HOLDERS OF ITS EXISTING WARRANTS FOR THE IMMEDIATE EXERCISE OF CERTAIN OUTSTANDING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 837,104 SHARES OF COMMON STOCK OF THE COMPANY ORIGINALLY ISSUED IN OCTOBER 2024 AT THEIR CURRENT EXERCISE PRICE OF $4.42 PER SHARE. THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE EXISTING WARRANTS ARE REGISTERED PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT ON FORM S-1 (FILE NO. 333-283091). THE AGGREGATE GROSS PROCEEDS FROM THE EXERCISE OF THE EXISTING WARRANTS IS EXPECTED TO TOTAL APPROXIMATELY $3.7 MILLION, BEFORE DEDUCTING FINANCIAL ADVISORY FEES.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES AGREEMENTSFOR EXERCISE OF WARRANTSFOR $3.7 MILLION GROSS PROCEEDS

PHOENIX, FEB. 14, 2025 (GLOBE NEWSWIRE) -- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. ("CREATIVE MEDICAL TECHNOLOGY" OR THE "COMPANY") (NASDAQ: CELZ), A PIONEERING BIOTECHNOLOGY FIRM SPECIALIZING IN REGENERATIVE MEDICINE SOLUTIONS FOR IMMUNOTHERAPY, ENDOCRINOLOGY, UROLOGY, GYNECOLOGY, AND ORTHOPEDICS, TODAY ANNOUNCED COMPELLING MID-TERM FOLLOW-UP DATA FROM ITS STEMSPINE PILOT STUDY UTILIZING ITS ALLOSTEM CELLS FOR THE TREATMENT OF CHRONIC LOWER BACK PAIN. THE PILOT STUDY DEMONSTRATED A SUBSTANTIAL REDUCTION IN OPIOID DEPENDENCY AND SIGNIFICANT IMPROVEMENTS IN PAIN LEVELS AND FUNCTIONAL MOBILITY.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS ANNOUNCES MID-TERM FOLLOW-UP STUDY DATA REPORTING SIGNIFICANT REDUCTION IN OPIOID USE BY CHRONIC LOWER BACK PAIN PATIENTS UNDERGOING STEMSPINE PROCEDURE USING ALLOSTEM

SIGNIFICANT EFFICACY AND NO SERIOUS ADVERSE EFFECTS OBSERVED WITH CELZ-201 SIGNIFICANT EFFICACY AND NO SERIOUS ADVERSE EFFECTS OBSERVED WITH CELZ-201

Creative Medical Technology Holdings, Inc.

CELZ

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Creative Medical Technology Holdings, Inc.

CELZ.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CELZ